Registry to analyze melanoma risk factors in Spain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to gather data on patients diagnosed with invasive primary cutaneous melanoma in Spain to identify socioeconomical and healthcare-related risk factors that may influence prognosis. The study will collect information on individual characteristics such as gender, residence area, and socioeconomic status, as well as healthcare factors like waiting times and the type of diagnostic center. Participants will be monitored without any changes to their treatment protocols, allowing for a comprehensive analysis of the factors affecting melanoma outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres.

Exclusion Criteria:

* In-situ melanomas
* non-cutaneous melanomas,
* metastatic melanoma with unknown primary site.

Where it's running

• Hospital Universitari Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital Clinic
  Barcelona, Spain Recruiting
• Hospital San Juan de Dios
  Córdoba, Spain Recruiting
• Hospital Universitario de Gran Canaria Dr Negrín
  Las Palmas, Spain Recruiting
• Complejo Asistencial Universitario de León
  León, Spain Recruiting
• Clínica Universitaria de Navarra ( sede de Madrid)
  Madrid, Spain Recruiting

Study contacts

• Study coordinator: Mercè Grau, MD
• Email: merce.grau@equipo.aedv.es
• Phone: 34 91 544 62 84

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Melanoma treatment with immunotherapy guided by serial ctDNA testing

  This trial tests whether regular ctDNA blood tests during treatment can help tailor the plan for patients with advanced melanoma receiving nivolumab and ipilimumab.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07930182

• Non-invasive skin-tape test to detect melanoma using methylation biomarkers

  A non-invasive skin-tape test is being tried to see if it can detect melanoma in people who are about to have a biopsy for a suspicious pigmented lesion.

  Recruiting at 4 sites Mitra Bio · Ghent and 4 other locations · NCT07883954

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• Aggressive lipid lowering in melanoma patients starting immune checkpoint therapy

  This trial tests whether lowering cholesterol aggressively can reduce heart artery disease risk in melanoma patients who are just beginning immune checkpoint therapy.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07704918

• Timing of Immunotherapy in Melanoma

  This trial tests whether starting standard melanoma immunotherapy earlier in the day (before 10 am) versus later in the day (after 1 pm) makes a difference for patients with unresectable or metastatic melanoma.

  Recruiting Radboud University Medical Center · Amsterdam and 4 other locations · NCT07696715

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.